Keros Therapeutics/$KROS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
$KROS
Sector
Primary listing
Employees
148
Headquarters
Website
KROS Metrics
BasicAdvanced
$638M
33.74
$0.47
1.07
-
Price and volume
Market cap
$638M
Beta
1.07
52-week high
$67.89
52-week low
$9.12
Average daily volume
393K
Financial strength
Current ratio
21.114
Quick ratio
20.398
Long term debt to equity
2.225
Total debt to equity
2.54
Profitability
EBITDA (TTM)
1.672
Gross margin (TTM)
94.23%
Net profit margin (TTM)
8.06%
Operating margin (TTM)
0.13%
Effective tax rate (TTM)
30.20%
Revenue per employee (TTM)
$1,570,000
Management effectiveness
Return on assets (TTM)
0.03%
Return on equity (TTM)
3.33%
Valuation
Price to earnings (TTM)
33.736
Price to revenue (TTM)
2.682
Price to book
0.9
Price to tangible book (TTM)
0.9
Price to free cash flow (TTM)
11.767
Free cash flow yield (TTM)
8.50%
Free cash flow per share (TTM)
1.334
Growth
Revenue change (TTM)
85,820.30%
Earnings per share change (TTM)
-109.11%
3-year revenue growth (CAGR)
126.64%
3-year earnings per share growth (CAGR)
-48.05%
What the Analysts think about KROS
Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
Bulls say / Bears say
Keros reported cash and cash equivalents of $720.5 million as of March 31, 2025, which management expects will fund operations into 2029 based on current assumptions (GlobeNewswire)
Revenue recognized under the global license agreement with Takeda helped reduce the Q2 net loss to $30.7 million, down from $45.3 million in Q2 2024, highlighting the value of strategic partnerships (GlobeNewswire)
The first patient dosing in the Phase 3 RENEW trial of Elritercept triggered a $10 million milestone payment from Takeda, de-risking the program’s development pathway (RTTNews)
Keros’ decision to discontinue the development of Cibotercept (KER-012) narrows its pipeline focus and forfeits potential opportunity in pulmonary arterial hypertension (GlobeNewswire)
The Board’s determination to return $375 million to shareholders shortens the cash runway to the first half of 2028, potentially constraining future R&D investments (GlobeNewswire)
Keros incurred combined R&D and G&A expenses of $58.0 million in Q2 2025, maintaining a high burn rate that may pressure liquidity over time (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
KROS Financial Performance
Revenues and expenses
KROS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Keros Therapeutics stock?
Keros Therapeutics (KROS) has a market cap of $638M as of October 12, 2025.
What is the P/E ratio for Keros Therapeutics stock?
The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 33.74 as of October 12, 2025.
Does Keros Therapeutics stock pay dividends?
No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Keros Therapeutics dividend payment date?
Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.
What is the beta indicator for Keros Therapeutics?
Keros Therapeutics (KROS) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.